Improving skin tests for patients with suspected allergies to iodinated contrast products
Optimization of the Skin Test Procedure With Iodinated Contrast Products for Certain Patients Suspected of Immediate Hypersensitivity
This study is testing if a new skin test method can better identify allergies to iodinated contrast products in patients who might be allergic.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06498219 on ClinicalTrials.gov |
What this trial studies
This observational study aims to optimize the skin test procedure for patients suspected of having immediate hypersensitivity to iodinated contrast products (ICPs). It focuses on evaluating the effectiveness of undiluted intradermal reactions (IDRs) compared to standard diluted tests in diagnosing allergic reactions. The study will include patients treated in the allergology department who have undergone at least one undiluted IDR to ICPs. The goal is to validate the relevance of these undiluted tests in identifying allergic mechanisms in affected patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been treated for suspected allergic hypersensitivity to iodinated contrast products and have undergone undiluted intradermal reactions.
Not a fit: Patients who have opposed the reuse of their data for scientific research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of allergies to iodinated contrast products, improving patient safety and management.
How similar studies have performed: While the approach of using undiluted IDRs has been practiced, this study aims to validate its effectiveness, making it a novel investigation in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major subject (≥18 years old) * Subject treated in the allergology department in the period from June 1, 2020 to July 3, 2023 for suspected allergic hypersensitivity to ICPs and having had at least one undiluted intradermal reaction to one or more ICPs. * Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. Exclusion Criteria: * Presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.
Where this trial is running
Strasbourg
- Service de Pneumologie - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Carine METZ-FAVRE, MD
- Email: carine.favre-metz@chru-strasbourg.fr
- Phone: 33 3 69 55 06 84
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.